Richard Conway RichardPAConway
4 years ago
Dr Jin @SeoyoungCKim population-based study on predictors of switching after 1st line TNFi use. 22% switch, most to 2nd TNFi.👩, prior steroid use predicted change, other autoimmune disease and vit D use negative predictors. Abstr#579 #ACR21 @RheumNow https://t.co/YpZ5rGBiod
Janet Pope Janetbirdope
4 years ago
‘Cool’ explanation for #COVID toes. Type I IFN response can drive perniosis. Great session of cases from Len Calabrese & Jack Cush @RheumNow #ACR21 7S001 usual suspects https://t.co/v8IX2xxOZ7
Robert B Chao, MD doctorRBC
4 years ago
2 year extension study on Upadacitinib in active AS
⭐️ASAS40 response maintained
⭐️MRI SPARCC scores decreased and maintained
⭐️infections most common AE
⭐️NO MACE, lymphoma, skin cancer, GI perforations
Abs#924
#ACR21 #ACRBest
@RheumNow
https://t.co/725IRAOgtW https://t.co/FVUoCi6aoQ
Eric Dein ericdeinmd
4 years ago
Jorge Plutzky, cardiologist perspective on RA at #ACR21
⭐️CANTOS: Canakinumab for MACE shows ⬇️ inflammation, no change in LDL. Improvement in MACE events
▶️Plutzky: "Proof of concept study"
@Rheumnow https://t.co/Xi9ZHxMtmu
Richard Conway RichardPAConway
4 years ago
Another benefit of DMARD use in RA. Dr Sood reports lower risk of long term opioid use. Very important given the harm of opioids Abstr#587 #ACR21 @RheumNow https://t.co/d1Dharf5jZ
Aurelie Najm AurelieRheumo
4 years ago
We need to control not only inflammation but also lipids levels in our patients w/ IA! Dr Plutzky brilliantly talking us through CV risk and RA showing data on how poor LDL control and coronary microvascular dysfunction lead to worse long term CV outcomes.
@RheumNow #ACR21 https://t.co/o6GWHDai5z
Richard Conway RichardPAConway
4 years ago
@MilenaGianfran @JYazdanyMD present on differential effects of biologics on CDAI in obese patients with rheumatoid arthritis. Abatacept better than TNFi in obese. Tocilizumab better than TNFi in non-obese. Abstr#0588 #ACR21 @RheumNow #ACRBest https://t.co/UcEpMAmNVw
Janet Pope Janetbirdope
4 years ago
Attaining low disease activity in #SLE ⬇️ mortality! More time in LLDAS = #lupus low disease activity state = ⬆️survival in >4000 pts with SLE. Also + was clinical remission on treatment CROT. Treat to a target has come to SLE @RheumNow #ACR21 abst0865 #ACRBest #RheumPix https://t.co/8ld8oncFRR
Dr. Antoni Chan synovialjoints
4 years ago
The drug retention for SEC and TNFi was similar in this RW study of 279 patients (TNFi 178, SEC 101).In subgroups analyses, age, BASDAI at diagnosis and BMI did not favour any group @RheumNow #ACR21 Abst#0911 https://t.co/g1tIy1qMX1 https://t.co/LHZMxMlzIB
TheDaoIndex KDAO2011
4 years ago
Dr. P Crow #PhilipHench provides a tour of research on SLE pathogenesis:
👉discovery of Ab to small nuclear RNAs and the spliceosome
👉T cells' role on B cell differentiation
👉⬆️CD40L on SLE lymphocytes
👉IFN genes and their effects on the immune system #ACR21 @rheumnow https://t.co/6v9O19UUxX
Robert B Chao, MD doctorRBC
4 years ago
No significant difference in effectiveness/treatment survival of different TNFi in axSpA
Failure of 1st TNFi did not diminish effectiveness of a second TNFi
Abs#938
#ACR21 @RheumNow
https://t.co/SLrOV7wmvU https://t.co/fkpmseVwF6
Md Yuzaiful Md Yusof Yuz6Yusof
4 years ago
#ACR21 #Abstr0686 A study used PET-CT to initially rule out cancer. Interestingly, they found ⬆️median muscle FDG uptake with PET-CT in IIM vs Non-IIM. Need further study on its added value compared to MRI/EMG @RheumNow https://t.co/F0B86ygjI9 https://t.co/eiJnqpU8ft
TheDaoIndex KDAO2011
4 years ago
Dr. P Crow #PhilipHenchLecture
IFN signature can parallel or predict flares #ACR21 @rheumnow https://t.co/OskxDuKPDH
Akhil Sood MD AkhilSoodMD
4 years ago
Abstr 0579
Kim & Colleagues examined predictors of Tx change among RA patients w/ TNFi as 1st line biologic agent
- Females & GC use more likely to switch agent
- Vitamin D use & hx of other immune-mediated diseases (eg. Psoriasis, IBD) less likely to switch
#ACR21 @RheumNow https://t.co/FM5mSWmSNA


Poster Hall